Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 24, 2024 - Issue 5
Submit an article Journal homepage
99
Views
0
CrossRef citations to date
0
Altmetric
Meeting Report

Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting

Hao Suna Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaView further author information
,
Haizhou Xingb Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaView further author information
,
Lijie Hanb Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaView further author information
,
Yongping Songb Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaView further author information
,
Zhongxing Jiangb Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaView further author information
,
Yanyan Liuc Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, ChinaCorrespondence[email protected]
View further author information
&
Jifeng Yub Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1217-4385View further author information
ORCID Icon show all
Pages 321-326 | Received 21 Jan 2024, Accepted 02 May 2024, Published online: 08 May 2024

References

  • Chauchet X, Cons L, Chatel L, et al. CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model. Exp Hematol Oncol. 2022 May 10;11(1):26. doi: 10.1186/s40164-022-00279-w
  • Sesques P, Houot R, Al Tabaa Y, et al. Glofitamab monotherapy in patients with Non-Hodgkin B-Cell Lymphoma after failing CAR T-Cell infusion: primary analysis of the bicar study, a phase II Lysa study. Blood. 2023;142(Supplement 1):893. doi: 10.1182/blood-2023-177703
  • Hutchings M, Carlo-Stella C, Morschhauser F, et al. Glofitamab monotherapy in relapsed or refractory large B-Cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-Cell therapy and by baseline total metabolic tumor volume. Blood. 2023;142(Supplement 1):433. doi: 10.1182/blood-2023-173951
  • Iacoboni G, Serna A, Garces VN, et al. Impact of prior bendamustine exposure on bispecific antibody treatment outcomes for patients with B-Cell lymphoma. Blood. 2023;142(Supplement 1):310. doi: 10.1182/blood-2023-184883
  • Iacoboni G, Crochet G, Couturier A, et al. Efficacy of chimeric antigen receptor T-Cell therapy is not impaired by previous bispecific antibody treatment in patients with large B-Cell lymphoma. Blood. 2023;142(Supplement 1):228. doi: 10.1182/blood-2023-185035
  • Schuster SJ, Sehn LH, Bartlett NL, et al. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal phase II study. Blood. 2023;142(Supplement 1):603. doi: 10.1182/blood-2023-173692
  • Linton K, Jurczak W, Lugtenburg P, et al. Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: first data disclosure from the epcore NHL-1 follicular lymphoma dose-expansion cohort. Blood. 2023;142(Supplement 1):1655. doi: 10.1182/blood-2023-179887
  • Crombie JL, Matasar M, Topp MS, et al. Odronextamab demonstrates durable complete responses in patients with diffuse large B-Cell lymphoma (DLBCL) progressing after CAR-T therapy: outcomes from the ELM-1 study. Blood. 2023;142(Supplement 1):4461. doi: 10.1182/blood-2023-181602
  • Ayyappan S, Kim WS, Kim TM, et al. Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed/refractory (R/R) diffuse large B-Cell lymphoma (DLBCL). Blood. 2023;142(Supplement 1):436. doi: 10.1182/blood-2023-179818
  • Song Y, Li Z, Li L, et al. GB261, an Fc-Function enabled and CD3 affinity De-tuned CD20/CD3 bispecific antibody, demonstrated a highly advantageous Safety/Efficacy balance in an ongoing first-in-human dose-escalation study in patients with relapsed/refractory Non-Hodgkin Lymphoma. Blood. 2023;142(Supplement 1):1719. doi: 10.1182/blood-2023-188444
  • Topp MS, Tani M, Dickinson M, et al. Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with Previously untreated diffuse large B-Cell lymphoma (DLBCL): a 12-month analysis from a phase ib study. Blood. 2023;142(Supplement 1):3085. doi: 10.1182/blood-2023-174081
  • Falchi L, Jardin F, Haioun C, et al. Glofitamab (glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with Previously untreated (1L) large B-Cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamics: preliminary safety and efficacy results. Blood. 2023;142(Supplement 1):858.
  • Morschhauser F, Patel K, Bobillo S, et al. Preliminary findings of a phase Ib/II trial indicate manageable safety and promising efficacy for mosunetuzumab in combination with lenalidomide (M+len) in Previously untreated (1L) Follicular Lymphoma (FL). Blood. 2023;142(Supplement 1):605. doi: 10.1182/blood-2023-174432
  • Hutchings M, Avigdor A, Balari AMS, et al. Glofitamab plus polatuzumab vedotin continues to demonstrate frequent and durable responses and has a manageable safety profile in patients with ≥2L Relapsed/Refractory DLBCL, including HGBCL, and in patients with prior CAR T-Cell therapy: updated results from a phase Ib/II study. Blood. 2023;142(Supplement 1):4460.
  • Budde LE, Olszewski AJ, Assouline S, et al. Mosunetuzumab plus polatuzumab vedotin demonstrates a favorable safety profile and efficacy in patients (pts) with relapsed or refractory (R/R) large B-Cell lymphoma (LBCL): primary analysis of a phase Ib/II study. Blood. 2023;142(Supplement 1):613. doi: 10.1182/blood-2023-174209
  • Mazza IA, Kim WS, Ko PS, et al. Subcutaneous epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-Cell lymphoma from EPCORE NHL-5. Blood. 2023;142(Supplement 1):438. doi: 10.1182/blood-2023-180089

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.